ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.461,52
-0,89%
S&P 500
5.580,94
-1,97%
Dow Jones
41.583,90
-1,69%
Euro vs US Dollar
1,08845
0,00%
Bitcoin
83.244,31
0,78%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Avalo Therapeutics Inc (AVTX)

  7. Avalo Therapeutics Inc (AVTX) News

AVTX

Avalo Therapeutics (AVTX)

Avalo Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AVTX
DatumZeitQuelleÜberschriftSymbolFirma
26/03/202512h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
26/03/202512h00GlobeNewswire Inc.Avalo Therapeutics Appoints Michael Heffernan as Chairman of the BoardNASDAQ:AVTXAvalo Therapeutics Inc
20/03/202512h06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AVTXAvalo Therapeutics Inc
20/03/202512h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
20/03/202512h00GlobeNewswire Inc.Avalo Reports 2024 Financial Results and Recent Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
24/02/202513h00GlobeNewswire Inc.Avalo Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:AVTXAvalo Therapeutics Inc
04/02/202514h00GlobeNewswire Inc.Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences ConferenceNASDAQ:AVTXAvalo Therapeutics Inc
30/01/202523h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
30/01/202523h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
30/01/202523h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
30/01/202523h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
13/01/202513h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
03/01/202522h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AVTXAvalo Therapeutics Inc
02/01/202513h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
02/01/202513h00GlobeNewswire Inc.Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy OfficerNASDAQ:AVTXAvalo Therapeutics Inc
31/12/202422h13Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVTXAvalo Therapeutics Inc
05/12/202413h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
14/11/202418h05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
12/11/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
12/11/202413h00GlobeNewswire Inc.Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement WarrantsNASDAQ:AVTXAvalo Therapeutics Inc
11/11/202413h00GlobeNewswire Inc.Avalo Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202423h00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AVTXAvalo Therapeutics Inc
07/11/202413h20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202413h17Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202413h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVTXAvalo Therapeutics Inc
07/11/202413h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
07/11/202413h00GlobeNewswire Inc.Avalo Reports Third Quarter 2024 Financial Results and Recent Business UpdatesNASDAQ:AVTXAvalo Therapeutics Inc
08/10/202413h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTXAvalo Therapeutics Inc
08/10/202413h00GlobeNewswire Inc.Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis SuppurativaNASDAQ:AVTXAvalo Therapeutics Inc
08/10/202402h06Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AVTXAvalo Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AVTX

Kürzlich von Ihnen besucht

NYSE
COF
Capital One Financial
BITMOT
864895
Bund Tf 0% Mg35 Eur
NASDAQ
TH
Target Hospitality
TSXV
CBIT
Cathedra Bitcoin
AMEX
ITRG
Integra Resources
Delayed Upgrade Clock
ADVFN Logo
Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten